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termore P-P'min prolongation is associated to RS maintenance. The effectiveness of 
VER in preventing AF recurrences is not related to trigger suppression, thus it is possible 
that its role in affecting the outcome of EC could involve action on electrical substrate 
Pts (N °) VER/STD (VER%) PACs (N °) P-P'min (msec) 
IRAF 21 3/18 (14%) * 10 ± 6 340 ± 99 ° 
ERAF 49 t 6/33 (33%) ° 6 ± 4 * 433 ± 169 °° 
SR 86 53/33 (62%) 6 ± 8 ** 488 ± 143 
p value * < 0,001 vs SR * = 0.002 vs IRAF ° < 0.0001 vs SR 
° = 0.02 vs SR ** < 0.04 vs IRAF °° < 0.05 vs IRAF e SR 
1042-115 High Recurrence Rate of Atrial Flutter After init ial 
Presentation in Patients on Drug Treatment: Case for 
Ablation as First Line Therapy 
Anvar A. Babaev. Valentin Suma, Cristina lira, Jonathan S. Steinberg, St. Luke's- 
Roosevelt Hospital~Columbia Universi~ New York, New York. 
Background: Despite the high succes rate of radiofrequency ablation, drug therapy is 
still considered the standard initial therapeutic approach for atrial flutter (AFL). We 
hypothesized that drug therapy of AFL at initial presentation does not provide effective 
long term control. 
Methods: We retrospectively studied the recurrence rate of AFL in all patients (pts) 
admitted to the hospital with a primary diagnosis of a new onset AFL over a 24 months 
period. Pts with a history of atrial fibrillation, alcohol abuse or recent cardiac surgery were 
excluded. A total of 53 pts were identified: 37 males, age 70+13 years, 57% with CAD, 
and EF 44_+20%. 
Results: All pts were converted to normal sinus rhythm by chemical, or chemical and 
electrical cardioversion. For AFL control, 11 pts were discharged on beta-blockers, 18 on 
calcium channel blockers, 7 on class III antiarrhythmic drug, 12 on combined therapy, 
and 5 pts on digoxin only. Over 2 years, 92% of the pts had a documented recurrent epi- 
sode of AFL (see Figure). 
Among group, 51% were hospitalized for symptoms caused by AFL, including 11% read- 
mitted twice, one pt with debilitating stroke, and 2 pts who died. The duration between ini- 
tial and second hospitalization was 7.9+8.9 months. 
Conclusions: AFL recurrence after initial presentation, cardioversion and drug treatment 
is almost 100%. Curative radiofrequency ablation of AFL should be considered a first line 
approach to avoid rehospitalization, and potential clinical consequences of the inevitable 
recurrence of AFL. 
1042-116 Safety of Outpatient Initiation of Antiarrhythmic Drugs 
for Maintenance of Sinus Rhythm After Conversion 
From Atrial Fibrillation or Atrial Flutter 
Thomas Hauser. Duane Pinto, Mark E. Josephson, Peter Zimetbaum, Beth Israe/ 
Deaconess Medical Center, Boston, Massachusetts, Harvard Medical School, Boston, 
Massachusetts. 
Background: Antierrhythmic drugs (AAD) are frequently utilized to maintain sinus 
rhythm (SR) in patients with atrial fibrillation (AF) or atrial flutter (AFI). Although often ini- 
tiated in an outpatient setting, there is little prospective evidence for the safety of this 
approach. 
Methods: 334 consecutive patients with a history of AF or AFi were prospectively moni- 
tored with an event recorder during the initiation of AADs. All AADs were initiated in SR. 
Patients transmitted a recording (30 seconds) once daily for t 0 consecutive days. 
Results: 168 (50%) received amiodarene, 113 (34%) received a type IC AAD, 31 (9%) 
received sotalol and 22 (7%) received a type IA AAD. 227 (58%) had an ejection fraction 
(EF) of >55%, 44 (13%) had an EF of >35% but <55% and 40 (12%) had an EF of <35%. 
No EF was available for 23 (7%), Major adverse events occurred during the monitoring 
period in 7 (2%) patients (see Table); 3 (1%) died, 1 (<1%) developed congestive heart 
failure and 3 (1%) developed bradycardia that required implantation of e permanent 
pacemaker. All adverse events occurred beyond the usual 48-hour period of in-hospital 
monitoring for AAD initiation. 
Conclusion: The outpatient initiation of AAD for patients with a history of AF or AFI while 
in SR is associated with significant risk. However, the adverse events occurred beyond 
the usual time period for in-hospital monitoring for AAD initiation. 
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Table: Adverse Events 
Adverse Event ~ Sex EF AAD Dosefmo/dav~ Dav 
Death 47 M 35% Quinidine (1A) 1944 3 
Death 92 M 55% Amiodarone 800 7 
Death 77 M 55% Amiodarone 400 9 
Congestive heart failure 70 F 35% Flecainide(1C) 200 6 
Bradycardia requiring pacing 84 M 55% Amiodarone 200 7 
Bradycardia requiring pacing 76 M 20% Amiodarone 1200 8 
Bradycardia requiring pacing 87 F 35% Amiodarone 800 8 
1042-117 Sotslol Reverses the Remodeled Action Potential in 
Patients With Chronic Atrial Fibrillation, but Does Not 
Prevent the Arrhythmia Recurrence 
Toshivuki Osaka, Eriko Yokoyama, Masatoshi Yamazaki, Atsushi Ito, Itsuo Kodama, 
Shizuoka Baiseikai General Hospital, Shizuoka City, Japan, Nagoya University, Nagoya, 
Japan. 
Background: Chronic atrial fibrillation (CAF) causes action potential lAP) remodeling of 
atrial muscle characterized by a shortening of the duration and a loss of the rate adapta- 
tion. Much remains to be clarified as to its clinical implication and pharmacological modi- 
fication. 
Methods: We recorded monephasic APs from the right atrium at 6 pacing cycle lengths 
(CLs) from 300 to 750 ms in 19 patients with CAF after cardioversion; 10 had no pretreat- 
ment (AF, 58±9 years), whereas 9 were pretreated with oral d, I-sotalol (SOT) (196±42 
my/day) for 7 days (AF-SOT, 55±11 years)Monophasic APs were recorded from 11 con- 
trol patients (58±10 years) as references. Twenty-four CAF patients (59±9 years) pre- 
treated with SOT (210±47 my/day) were followed up 2 weeks after cardioversion. 
Results: APD at 90% repoladzation (APDg0) in control increased lineady with increases 
of CL. In AF, the CL-APD90 relation was shifted downward and flattened at longer CLs, 
giving rise to shorter APDgOs than in control at CLs > 400 ms (Table). In AF-SOT, 
APD90s were longer than in AF at 6 CLs tested; the prolongation was greater at longer 
CLs, resulting in a similar rate-adaptation to that for control. AF recurred in 14 out of 24 
CAF patients despite of continuous treatment with SOT. 
Conclusion: The loss of rate adaptation of APD in patients with CAF is apparently 
reversed by SOT via its greater Class III action at longer CLs. This effect, however, dose 
not prevent the AF recurrence, suggesting that AP remodeling may not solely explain the 
early recurrence. 
APD9O (ms) 
Cycle Length (ms) 300 333 400 500 600 750 
Control (n=11) 209±19 221±19 239±23 251±25 258±26 264±28 
AF (n=10) 206±11 214±12 223±15 229±18" 229±15" 227±16" 
AF-SOT (n=9) 226±19# 240±23# 257±32# 269±42# 275±42# 282±46# 
*p<0.O5 versus Control, #p<0.05 versus AF, mean±SD 
1042-118 Supplementary Bepridil Potentiates Antifibrillatory 
Effects of Amiodarone by Modulating the Frequency- 
Dependence of Atrial Action Potential Prolongation 
Toshivuki Osaka, Eriko Yokoyama, Atsushi Ito, Itsuo Kodama, Shizuoka Saiseikai 
General Hospital, Shizuoka Ci~ Japan, Nagoya Universi~ Nagoya, Japan. 
Background: The high efficacy of amiodarene (AM) in preventing recurrence of atrial 
fibrillation (AF) has been proven in large-scale clinical trials, but its use, especially at 
higher doses, is still limited because of the serious side effects. We examined the anti- 
fibrillatory effects of supplementary application of bepddil (BP) on patients (pts) with AM- 
resistant AF. 
Methods: Monophasic action potentials lAPs) were recorded from the right atrium in 23 
pts (63±10 years) with recurrent AF or ventricular tachyarrhythmias after 3-week treat- 
ment with oral AM (200 my/day, n=9), BP (200 my/day, n=11) or AM (175±45 my/day) 
plus BP (110±22 my/day)in=5). APs recorded from 13 pts (65±8 years) without drug 
therapy were used as control. In 9 pts with recurrent AF unresponsive to AM (131±37 
my/day) alone, BP (t 25±38 my/day) was added to see the antifibrillatory effect. 
Results: AP durations at 90% repolarization (APD90s) in AM, BP and AM+BP groups 
were longer than those in control at 5 pacing cycle lengths (Table). The APD prolongation 
at longer cycle lengths was comparable (AM 12.3%, BP 14.8%, AM+BP 15.2% at 750 
ms), whereas the prolongation at the shortest cycle length (333 ms) in AM+BP (23.9%) 
was greater than in AM (11.5%) or BP (15.5%) alone. AF recurrence was prevented for > 
6 months in 7 of 9 AM-treated pts after additional application of BP. 
Conclusion: Supplementary application of BP potentiates the AM action to prevent AF 
recurrence. This effect may be the result of an enhancement of APD prolongation at high 
atrial rates. 
APD90 (ms) 
Cycle Length (ms) 333 400 500 600 750 
Control (n=l 3) 226±22 247±32 257±32 269±33 277±38 
AM (n=9) 252±15" 271±20" 288±22* 298±25* 311±28" 
BP (n=11) 261±14" 284±19" 298±22* 311±26" 318±33" 
AM+BP (n=5) 280±11"# 294±11" 303±15" 313±15" 319±13" 
*p<0.05 versus CON, #p<0.05 versus AM or BP, mean±SD 
